Royalty Pharma Plc Class A (RPRX)

RPRX · Health Care · United States

Royalty Pharma Plc Class A (RPRX) is a company in the Health Care sector, based in United States. The stock is held in 20 ETFs we track – with its largest weight of 0.39 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Royalty Pharma Plc.

Above-average ETF coverage: 20 of the 95 ETFs we cover hold Royalty Pharma Plc, spread across 10 indices. That puts the stock in more ETFs than 82.9 % of the 4,334 stocks we cover.

Held in20 ETFs

Highest weight0.39 %

Indices10

SectorHealth Care

CountryUnited States

ISINGB00BMVP7Y09

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date	+51.3 %	1 year	+65.1 %
1 month	-1.6 %	3 months	+8.9 %
Calendar year 2025	+51.5 %

52W

Data note 3

Measured in euros, Royalty Pharma Plc returned +54.1 % year to date and +68.9 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-17.0 %

Volatility p.a.23.5 %

Data note 5

Below peak-8.6 %

Beta to S&P 5000.27

Correlation to S&P 5000.15

The close on Sep 16, 2026 was 8.6 % below the highest close since Aug 12, 2024, reached on Sep 4, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Royalty Pharma Plc moved on average 0.27 % in the same direction. The correlation of 0.15 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
Amgen Inc.	+0.69
Bristol-Myers Squibb Company	+0.60
Vertex Pharmaceuticals Incorporated	+0.57
AbbVie Inc.	+0.55
Gilead Sciences Inc.	+0.55
Eli Lilly and Company	+0.53
Coherent Corp.	-0.29
Lumentum Holdings Inc.	-0.29
Toncoin	-0.29

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue2.4 bn $

Net income0.8 bn $

Diluted EPS1.78 $

Net margin32.4 %

Revenue growth+5.1 %

Revenue and profit by fiscal year
Fiscal year	Revenue	Net income	Margin
FY2023	2.4	1.1	48.2 %
FY2024	2.3	0.9	37.9 %
FY2025	2.4	0.8	32.4 %

Data note 8

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	0.39 %	€3.90
XDWH	msci-world-health-care	0.29 %	€2.90
SPFS	msci-world-health-care	0.29 %	€2.90
XDEV	msci-world-value	0.15 %	€1.50
XDEM	msci-world-momentum	0.12 %	€1.20
2B7K	msci-world-sri	0.11 %	€1.10
WVAL	msci-world-value	0.09 %	€0.90
SWWD	msci-world	0.04 %	€0.40
SPPW	msci-world	0.04 %	€0.40
XD9U / XD9D	msci-usa	0.04 %	€0.40
EUNL	msci-world	0.03 %	€0.30
XDWD / XDWL	msci-world	0.03 %	€0.30
WIMI	msci-world-imi	0.02 %	€0.20
SPYY	msci-acwi	0.02 %	€0.20
IUSQ	msci-acwi	0.02 %	€0.20
SPYI / SPSA	msci-acwi-imi	0.01 %	€0.10

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Royalty Pharma Plc as of the fund's latest holdings list.

Weight in EUNL since 2020

Dec 31, 2020Sep 16, 2026

In EUNL, a fund tracking the MSCI World, Royalty Pharma Plc had a weight of 0.01 % on Dec 31, 2020 and 0.03 % on Sep 16, 2026. Its share peaked at 0.03 % on Jun 30, 2022. The weight rises and falls with the stock's price relative to the other index members, and it also shifts when the index provider changes the composition.

Data note 10

How much Royalty Pharma Plc Class A overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Royalty Pharma Plc — the figure counts the ETFs holding both.

Data note 11

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Royalty Pharma Plc	+65.1 %	23.5 %	32.4 %	+5.1 %
Biogen	+50.3 %	32.2 %	13.1 %	+2.2 %
Illumina	+125.6 %	45.3 %	19.6 %	-0.7 %
Roivant Sciences	+179.1 %	39.6 %	-3629.2 %	-71.6 %
Revolution Medicines	+338.3 %	56.9 %	–	–
Centene Corporation	+107.6 %	51.4 %	-3.8 %	+20.0 %
Cooper Companies	-16.2 %	33.6 %	9.2 %	+5.1 %
Zimmer Biomet Holdings	-2.4 %	29.6 %	8.6 %	+7.2 %
CVS Health Corporation	+24.8 %	34.0 %	0.4 %	+7.8 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.